Sepsis, coagulation and anticoagulants

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 10, Issue 3, 2010, Pages 204-213

  Machado, Flavia Ribeiro ^a   Cesar, Murillo Santucci ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antithrombin; Disseminated intravascular coagulation; Inflammation mediators; Protein c; Sepsis; Tissue factor pathway inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; DROTRECOGIN; FIBRIN; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLEEDING; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVITY; FIBRINOLYSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; PLATELET MICROPARTICLE; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION;

EID: 78549277182     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153010791936892     Document Type: Article

References (136)

1. Bone, R.C.; Balk, R.A.; Cerra, F.B.; Dellinger, R.P.; Fein, A.M.; Knaus, W.A.; Schein, R.M. and Sibbald, W.J. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 101, 1644-1655.
2. Levi, M. and Ten Cate, H. (1999) Disseminated intravascular coagulation. N. Engl. J. Med., 341, 586-592.
3. Colman, R.W.; Robboy, S.J. and Minna, J.D. (1979) Disseminated intravascular coagulation: a reappraisal. Annu. Rev. Med., 30, 359- 374.
4. Levi, M.; de Jonge, E.; van der Poll, T. and ten Cate, H. (1999) Disseminated intravascular coagulation. Thromb. Haemost., 82, 695-705.
5. Spicer, E.K.; Horton, R.; Bloem, L.; Bach, R.; Williams, K.R.; Guha, A.; Kraus, J.; Lin, T.C.; Nemerson, Y. and Konigsberg, W.H. (1987) Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc. Natl. Acad. Sci. USA, 84, 5148-5152.
6. Ruf, W.; Rehemtulla, A.; Morrissey, J.H. and Edgington, T.S. (1991) Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J. Biol. Chem., 266, 16256.
7. Komiyama, Y.; Pedersen, A.H. and Kisiel, W. (1990) Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry, 29, 9418-9425.
8. Censarek, P.; Bobbe, A.; Grandoch, M.; Schror, K.; and Weber, A. A. (2007) Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb. Haemost., 97, 11-14.
9. Hobbs, J.E.; Zakarija, A.; Cundiff, D.L.; Doll, J.A.; Hymen, E.; Cornwell, M.; Crawford, S.E.; Liu, N.; Signaevsky, M. and Soff, G.A. (2007) Alternatively spliced human tissue factor promotes
10. Osterud, B. and Flaegstad, T. (1983) Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb. Haemost., 49, 5-7.
11. van der Poll, T.; Levi, M.; Hack, C.E.; ten Cate, H.; van Deventer, S.J.; Eerenberg, A.J.; de Groot, E.R.; Jansen, J.; Gallati, H.; and Buller, H.R. (1994) Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J. Exp. Med., 179, 1253-1259.
12. [12] Levi, M.; van der Poll, T.; ten Cate, H. and van Deventer, S.J. (1997)The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur. J. Clin. Invest., 27, 3-9.
13. Banner, D.W.; D'Arcy, A.; Chene, C.; Winkler, F.K.; Guha, A.; Konigsberg, W.H.; Nemerson, Y. and Kirchhofer, D. (1996) The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature, 380, 41-46.
14. Bjoern, S.; Foster, D.C.; Thim, L.; Wiberg, F.C.; Christensen, M.; Komiyama, Y.; Pedersen, A.H. and Kisiel, W. (1991) Human plasma and recombinant factor VII. Characterization of O- glycosylations at serine residues 52 and 60 and effects of site- directed mutagenesis of serine 52 to alanine. J. Biol. Chem., 266, 11051-11057.
15. Biemond, B.J.; Levi, M.; Coronel, R.; Janse, M.J.; ten Cate, J.W. and Pannekoek, H. (1995) Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation, 91, 1175-1181.
16. de Jonge, E.; Dekkers, P.E.; Creasey, A.A.; Hack, C.E.; Paulson, S.K.; Karim, A.; Kesecioglu, J.; Levi, M.; van Deventer, S.J. and van Der Poll, T. (2000) Tissue factor pathway inhibitor dose- dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood, 95, 1124-1129.
17. Levi, M.; ten Cate, H.; Bauer, K.A.; van der Poll, T.; Edgington, T.S.; Buller, H.R.; van Deventer, S.J.; Hack, C.E.; ten Cate, J.W. and Rosenberg, R.D. (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J. Clin. Invest., 93, 114-120.
18. de Pont, A.C.; Moons, A.H.; de Jonge, E.; Meijers, J.C.; Vlasuk, G.P.; Rote, W.E.; Buller, H.R.; van der Poll, T. and Levi, M. (2004) Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. J. Thromb. Haemost., 2, 65-70.
19. Monroe, D.M. and Key, N.S. (2007) The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J. Thromb. Haemost., 5, 1097-1105.
20. Tang, H.; Ivanciu, L.; Popescu, N.; Peer, G.; Hack, E.; Lupu, C.; Taylor, F.B.Jr. and Lupu, F. (2007) Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am. J. Pathol., 171, 1066-1077.
21. van Till, J.W.; Levi, M.; Bresser, P.; Schultz, M.J.; Gouma, D.J. and Boermeester, M.A. (2006) Early procoagulant shift in the bronchoalveolar compartment of patients with secondary peritonitis. J. Infect. Dis., 194, 1331-1339.
22. Bastarache, J.A.; Wang, L.; Geiser, T.; Wang, Z.; Albertine, K.H.; Matthay, M.A. and Ware, L.B. (2007) The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax, 62, 608-616.
23. Bastarache, J.A.; Wang, L.; Wang, Z.; Albertine, K.H.; Matthay, M.A. and Ware, L.B. (2008) Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am. J. Physiol. Lung Cell Mol. Physiol., 294, L874-881.
24. Gunther, A.; Mosavi, P.; Heinemann, S.; Ruppert, C.; Muth, H.; Markart, P.; Grimminger, F.; Walmrath, D.; Temmesfeld- Wollbruck, B. and Seeger, W. (2000) Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am. J. Respir. Crit. Care. Med., 161, 454-462.
25. Choi, G.; Wolthuis, E.K.; Bresser, P.; Levi, M.; van der Poll, T.; Dzoljic, M.; Vroom, M.B. and Schultz, M.J. (2006) Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology, 105, 689-695.
26. Coppinger, J.A.; Cagney, G.; Toomey, S.; Kislinger, T.; Belton, O.; McRedmond, J.P.; Cahill, D.J.; Emili, A.; Fitzgerald, D.J. and Maguire, P.B. (2004) Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood, 103, 2096-2104.
27. Semple, J.W. and Freedman, J. (2010) Platelets and innate immunity. Cell Mol. Life Sci., 67, 499-511.
28. Sprague, D.L.; Sowa, J.M.; Elzey, B.D. and Ratliff, T.L. (2007) The role of platelet CD154 in the modulation in adaptive immunity. Immunol. Res., 39, 185-193.
29. Sun, H.; Wang, X.; Degen, J.L. and Ginsburg, D. (2009) Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood, 113, 1358-1364.
30. Yeaman, M.R. (2010) Platelets in defense against bacterial pathogens. Cell Mol. Life Sci., 67, 525-544.
31. Colman, R.W. (1991) Receptors that activate platelets. Proc. Soc. Exp. Biol. Med., 197, 242-248.
32. Heijnen, H.F.; Schiel, A.E.; Fijnheer, R.; Geuze, H.J. and Sixma, J. J. (1999) Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood, 94, 3791-3799.
33. George, F.D. (2008) Microparticles in vascular diseases. Thromb. Res., 122(Suppl 1), S55-59.
34. Ogura, H.; Kawasaki, T.; Tanaka, H.; Koh, T.; Tanaka, R.; Ozeki, Y.; Hosotsubo, H.; Kuwagata, Y.; Shimazu, T. and Sugimoto, H. (2001) Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J. Trauma, 50, 801-809.
35. Aras, O.; Shet, A.; Bach, R.R.; Hysjulien, J.L.; Slungaard, A.; Hebbel, R.P.; Escolar, G.; Jilma, B. and Key, N.S. (2004) Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood, 103, 4545-4553.
36. Nieuwland, R.; Berckmans, R.J.; McGregor, S.; Boing, A.N.; Romijn, F.P.; Westendorp, R.G.; Hack, C.E. and Sturk, A. (2000) Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood, 95, 930-935.
37. Kushak, R.I.; Nestoridi, E.; Lambert, J.; Selig, M.K.; Ingelfinger, J.R. and Grabowski, E.F. (2005) Detached endothelial cells and microparticles as sources of tissue factor activity. Thromb. Res., 116, 409-419.
38. Mortaza, S.; Martinez, M.C.; Baron-Menguy, C.; Burban, M.; de la Bourdonnaye, M.; Fizanne, L.; Pierrot, M.; Cales, P.; Henrion, D.; Andriantsitohaina, R.; Mercat, A.; Asfar, P. and Meziani, F. (2009) Detrimental hemodynamic and inflammatory effects of microparticles originating from septic rats. Crit. Care Med., 37, 2045-2050.
39. Soriano, A.O.; Jy, W.; Chirinos, J.A.; Valdivia, M.A.; Velasquez, H.S.; Jimenez, J.J.; Horstman, L.L.; Kett, D.H.; Schein, R.M. and Ahn, Y.S. (2005) Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit. Care Med., 33, 2540-2546.
40. Riewald, M. and Ruf, W. (2001) Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc. Natl. Acad. Sci. USA, 98, 7742-7747.
41. Camerer, E.; Cornelissen, I.; Kataoka, H.; Duong, D.N.; Zheng, Y.W. and Coughlin, S.R. (2006) Roles of protease-activated receptors in a mouse model of endotoxemia. Blood, 107, 3912- 3921.
42. [42] Kaneider, N.C.; Leger, A.J.; Agarwal, A.; Nguyen, N.; Perides, G.; Derian, C.; Covic, L. and Kuliopulos, A. (2007) 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat. Immunol., 8, 1303-1312.
43. Niessen, F.; Schaffner, F.; Furlan-Freguia, C.; Pawlinski, R.; Bhattacharjee, G.; Chun, J.; Derian, C.K.; Andrade-Gordon, P.; Rosen, H. and Ruf, W. (2008) Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature, 452, 654-658.
44. Valentin, S.; Nordfang, O.; Bregengard, C. and Wildgoose, P. (1993) Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood. Coagul. Fibrinol., 4, 713-720.
45. Enjyoji, K.; Miyata, T.; Kamikubo, Y. and Kato, H. (1995) Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry, 34, 5725-5735.
46. Broze, G.J. Jr.; Girard, T.J. and Novotny, W.F. (1990) Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry, 29, 7539-7546.
47. Hack, C.E. (2000) Tissue factor pathway of coagulation in sepsis. Crit. Care Med., 28 (9 Suppl), S25-S30.
48. Huang, Z.F.; Wun, T.C. and Broze, G.J.Jr. (1993) Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J. Biol. Chem., 268, 26950-26955.
49. Kato, H. (2002) Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler. Thromb. Vasc. Biol., 22, 539-548.
50. Creasey, A.A. and Reinhart, K. (2001) Tissue factor pathway inhibitor activity in severe sepsis. Crit. Care Med., 29, S126-S129.
51. Goldfarb, R.D.; Glock, D.; Johnson, K.; Creasey, A.A.; Carr, C.; McCarthy, R.J.; Matushek, M.; Akhter, I.; Trenholme, G. and Parrillo, J.E. (1998) Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock, 10, 258-264.
52. Camerota, A.J.; Creasey, A.A.; Patla, V.; Larkin, V.A. and Fink, M.P. (1998) Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram- negative peritonitis. J. Infect. Dis., 177, 668-676.
53. Enkhbaatar, P.; Okajima, K.; Uchiba, M.; Isobe, H. and Okabe, H. (2001) Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide. Thromb. Haemost., 86, 1573-1577.
54. de Jonge, E.; Dekkers, P.E.; Creasey, A.A.; Hack, C.E.; Paulson, S.K.; Karim, A.; Kesecioglu, J.; Levi, M.; van Deventer, S.J. and van der Poll, T. (2001) Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J. Infect. Dis., 183, 1815-1818.
55. Ye, Z.; Takano, R.; Hayashi, K.; Ta, T.V.; Kato, H.; Kamikubo, Y.; Nakahara, Y.; Kumeda, K. and Hara, S. (1998) Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction. Thromb. Res., 89, 263-270.
56. Gando, S.; Kameue, T.; Morimoto, Y.; Matsuda, N.; Hayakawa, M. and Kemmotsu, O. (2002) Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit. Care Med., 30, 1729-1734.
57. Rapaport, S.I. and Rao, L.V. (1992) Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler. Thromb., 12, 1111-1121.
58. Belaaouaj, A.A.; Li, A.; Wun, T.C.; Welgus, H.G. and Shapiro, S.D. (2000) Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J. Biol. Chem., 275, 27123-27128.
59. Griffin, J.H.; Fernandez, J.A.; Gale, A.J. and Mosnier, L.O. (2007) Activated protein C. J. Thromb. Haemost., 5, 73-80.
60. Gruber, A. and Griffin, J.H. (1992) Direct detection of activated protein C in blood from human subjects. Blood, 79, 2340-2348.
61. [61] Esmon, C.T. (2003) The protein C pathway. Chest, 124, 26S-32S.
62. Toltl, L.J.; Beaudin, S. and Liaw, P.C. (2008) Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. J. Immunol., 183, 2165-2173.
63. Comp, P.C. and Esmon, C.T. (1981) Generation of fibrinolytic activity by infusion of activated protein C into dogs. J. Clin. Invest., 68, 1221-1228.
64. Krishnamurti, C.; Young, G.D.; Barr, C.F.; Colleton, C.A. and Alving, B.M. (1991) Enhancement of tissue plasminogen activator- induced fibrinolysis by activated protein C in endotoxin-treated rabbits. J. Lab. Clin. Med., 118, 523-530.
65. ten Cate, H. (2000) Pathophysiology of disseminated intravascular coagulation in sepsis. Crit. Care Med., 28, S9-S11.
66. Joyce, D.E.; Gelbert, L.; Ciaccia, A.; DeHoff, B. and Grinnell, B.W. (2001) Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem., 276, 11199-11203.
67. Riewald, M.; Petrovan, R.J.; Donner, A.; Mueller, B.M. and Ruf, W. (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 296, 1880-1882.
68. Mosnier, L.O. and Griffin, J.H. (2003) Inhibition of staurosporine- induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem. J., 373, 65-70.
69. Song, D.; Ye, X.; Xu, H. and Liu, S.F. (2009) Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood, 114, 2521-2529.
70. Cheng, T.; Liu, D.; Griffin, J.H.; Fernandez, J.A.; Castellino, F.; Rosen, E.D.; Fukudome, K. and Zlokovic, B.V. (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med., 9, 338-342.
71. Sennoun, N.; Meziani, F.; Dessebe, O.; Cattan, V.; Collin, S.; Montemont, C.; Gibot, S.; Asfar, P.; Ramaroson, A.; Regnault, V.; Slama, M.; Lecompte, T.; Lacolley, P. and Levy, B. (2009) Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit. Care Med., 37, 246-255.
72. Abraham, E. (2005) Effects of recombinant human activated protein C in human models of endotoxin administration. Proc. Am. Thorac. Soc., 2, 243-247.
73. Robriquet, L.; Collet, F.; Tournoys, A.; Prangere, T.; Neviere, R.; Fourrier, F. and Guery, B.P. (2006) Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir. Res., 7, 41.
74. Feistritzer, C. and Riewald, M. (2005) Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood, 105, 3178-3184.
75. Finigan, J.H.; Dudek, S.M.; Singleton, P.A.; Chiang, E.T.; Jacobson, J.R.; Camp, S.M.; Ye, S.Q. and Garcia, J.G. (2005) Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J. Biol. Chem., 280, 17286-17293.
76. Schuepbach, R.A.; Feistritzer, C.; Fernandez, J.A.; Griffin, J.H. and Riewald, M. (2009) Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb. Haemost., 101, 724-733.
77. Murakami, K.; Okajima, K.; Uchiba, M.; Johno, M.; Nakagaki, T.; Okabe, H. and Takatsuki, K. (1996) Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood, 87, 642-647.
78. Nick, J.A.; Coldren, C.D.; Geraci, M. W.; Poch, K. R.; Fouty, B. W.; O'Brien, J.; Gruber, M.; Zarini, S.; Murphy, R.C.; Kuhn, K.; Richter, D.; Kast, K.R. and Abraham, E. (2004) Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood, 104, 3878-3885.
79. Feistritzer, C.; Sturn, D.H.; Kaneider, N.C.; Djanani, A. and Wiedermann, C.J. (2003) Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J. Allergy Clin. Immunol., 112, 375-381.
80. Mosnier, L.O.; Gale, A.J.; Yegneswaran, S. and Griffin, J.H. (2004) Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood, 104, 1740-1744.
81. Kerschen, E.J.; Fernandez, J.A.; Cooley, B.C.; Yang, X.V.; Sood, R.; Mosnier, L.O.; Castellino, F.J.; Mackman, N.; Griffin, J.H. and Weiler, H. (2007) Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J. Exp. Med., 204, 2439- 2448.
82. Bernard, G.R.; Vincent, J.L.; Laterre, P.F.; LaRosa, S.P.; Dhainaut, J.F.; Lopez-Rodriguez, A.; Steingrub, J.S.; Garber, G.E.; Helterbrand, J.D.; Ely, E.W. and Fisher, C.J. Jr. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 344, 699-709.
83. Abraham, E.; Reinhart, K.; Opal, S.; Demeyer, I.; Doig, C.; Rodriguez, A.L.; Beale, R.; Svoboda, P.; Laterre, P.F.; Simon, S.; Light, B.; Spapen, H.; Stone, J.; Seibert, A.; Peckelsen, C.; De Deyne, C.; Postier, R.; Pettila, V.; Artigas, A.; Percell, S.R.; Shu, V.; Zwingelstein, C.; Tobias, J.; Poole, L.; Stolzenbach, J.C. and Creasey, A.A. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA, 290, 238-247.
84. Warren, B.L.; Eid, A.; Singer, P.; Pillay, S.S.; Carl, P.; Novak, I.; Chalupa, P.; Atherstone, A.; Penzes, I.; Kubler, A.; Knaub, S.; Keinecke, H.O.; Heinrichs, H.; Schindel, F.; Juers, M.; Bone, R.C. and Opal, S.M. (2001) Caring for the critically ill patient. High- dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA, 286, 1869-1878.
85. Fukudome, K. and Esmon, C.T. (1994) Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J. Biol. Chem., 269, 26486-26491.
86. Conway, E.M. and Rosenberg, R.D. (1988) Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol. Cell. Biol., 8, 5588-5592.
87. Esmon, C.T.; Xu, J.; Gu, J.M.; Qu, D.; Laszik, Z.; Ferrell, G.; Stearns-Kurosawa, D.J.; Kurosawa, S.; Taylor, F.B.Jr. and Esmon, N.L. (1999) Endothelial protein C receptor. Thromb. Haemost., 82, 251-258.
88. Oelschlager, C.; Romisch, J.; Staubitz, A.; Stauss, H.; Leithauser, B.; Tillmanns, H. and Holschermann, H. (2002) Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood, 99, 4015-4020.
89. Harada, N.; Okajima, K.; Kushimoto, S.; Isobe, H. and Tanaka, K. (1999) Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood, 93, 157-164.
90. Uchiba, M.; Okajima, K.; Murakami, K.; Okabe, H. and Takatsuki, K. (1996) Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am. J. Physiol., 270, L921-L930.
91. Roemisch, J.; Gray, E.; Hoffmann, J.N. and Wiedermann, C.J. (2002) Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul. Fibrinol., 13, 657-670.
92. Mansell, A.; Reinicke, A.; Worrall, D.M. and O'Neill, L.A. (2001) The serine protease inhibitor antithrombin III inhibits LPS- mediated NF-kappaB activation by TLR-4. FEBS Lett., 508, 313-317.
93. Ostrovsky, L.; Woodman, R.C.; Payne, D.; Teoh, D. and Kubes, P. (1997) Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation, 96, 2302-2310.
94. Yamashiro, K.; Kiryu, J.; Tsujikawa, A.; Honjo, M.; Nonaka, A.; Miyamoto, K.; Honda, Y.; Tanihara, H. and Ogura, Y. (2001) Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest. Ophthalmol. Vis. Sci., 42, 1553-1560.
95. Kaneider, N.C.; Reinisch, C.M.; Dunzendorfer, S.; Romisch, J. and Wiedermann, C.J. (2002) Syndecan-4 mediates antithrombin- induced chemotaxis of human peripheral blood lymphocytes and monocytes. J. Cell. Sci., 115, 227-236.
96. Feistritzer, C.; Kaneider, N.C.; Sturn, D.H. and Wiedermann, C.J. (2004) Syndecan-4-dependent migration of human eosinophils. Clin. Exp. Allergy, 34, 696-703.
97. Justus, A.C.; Roussev, R.; Norcross, J.L. and Faulk, W.P. (1995) Antithrombin binding by human umbilical vein endothelial cells: effects of exogenous heparin. Thromb. Res., 79, 175-186.
98. Kaneider, N.C.; Egger, P.; Dunzendorfer, S. and Wiedermann, C.J. (2001) Syndecan-4 as antithrombin receptor of human neutrophils. Biochem. Biophys. Res. Commun., 287, 42-46.
99. Pulletz, S.; Lehmann, C.; Volk, T.; Schmutzler, M.; Ziemer, S.; Kox, W.J. and Scherer, R.U. (2000) Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit. Care Med., 28, 2881-2886.
100. Opal, S.M.; Kessler, C.M.; Roemisch, J. and Knaub, S. (2002) Antithrombin, heparin, and heparan sulfate. Crit. Care Med., 30, S325-S331.
101. Danese, S.; Vetrano, S.; Zhang, L.; Poplis, V.A. and Castellino, F.J. (2010) The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood, 115, 1121-1130.
102. Weyrich, A.S.; Schwertz, H.; Kraiss, L.W. and Zimmerman, G.A. (2009) Protein synthesis by platelets: historical and new perspectives. J. Thromb. Haemost., 7, 241-246.
103. Mileno, M.D.; Margolis, N.H.; Clark, B.D.; Dinarello, C.A.; Burke, J.F. and Gelfand, J.A. (1995) Coagulation of whole blood stimulates interleukin-1 beta gene expression. J. Infect. Dis., 172, 308-311.
104. Johnson, K.; Choi, Y.; DeGroot, E.; Samuels, I.; Creasey, A. and Aarden, L. (1998) Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J. Immunol., 160, 5130-5135.
105. Sugama, Y.; Tiruppathi, C.; offakidevi, K.; Andersen, T.T.; Fenton, J.W.(1992)Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. J. Cell. Biol., 119, 935-944.
106. Ossovskaya, V.S. and Bunnett, N.W. (2004) Protease-activated receptors: contribution to physiology and disease. Physiol. Rev., 84, 579-621.
107. Coughlin, S.R. (2000) Thrombin signalling and protease-activated receptors. Nature, 407, 258-264.
108. Chen, D. and Dorling, A. (2009) Critical roles for thrombin in acute and chronic inflammation. J. Thromb. Haemost., 7, 122-126.
109. Sower, L.E.; Froelich, C.J.; Carney, D.H.; Fenton, J.W. 2nd and Klimpel, G.R. (1995) Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J. Immunol., 155, 895-901.
110. van der Poll, T.; de Jonge, E. and Levi, M. (2001) Regulatory role of cytokines in disseminated intravascular coagulation. Semin. Thromb. Hemost., 27, 639-651.
111. van der Poll, T.; Levi, M.; van Deventer, S.J.; ten Cate, H.; Haagmans, B.L.; Biemond, B.J.; Buller, H.R.; Hack, C.E. and ten Cate, J.W. (1994) Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood, 83, 446-451.
112. van der Poll, T.; Coyle, S.M.; Levi, M.; Jansen, P.M.; Dentener, M.; Barbosa, K.; Buurman, W.A.; Hack, C.E.; ten Cate, J.W.; Agosti, J.M. and Lowry, S.F. (1997) Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood, 89, 3727-3734.
113. Stouthard, J.M.; Levi, M.; Hack, C.E.; Veenhof, C.H.; Romijn, H.A.; Sauerwein, H.P. and van der Poll, T. (1996) Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb. Haemost., 76, 738-742.
114. Fischer, E.; Marano, M.A.; Van Zee, K.J.; Rock, C.S.; Hawes, A.S.; Thompson, W.A.; DeForge, L.; Kenney, J.S.; Remick, D.G. and Bloedow, D.C. (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J. Clin. Invest., 89, 1551-1557.
115. Jansen, P.M.; Boermeester, M.A.; Fischer, E.; de Jong, I.W.; van der Poll, T.; Moldawer, L.L.; Hack, C.E. and Lowry, S.F. (1995) Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory- type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood, 86, 1027-1034.
116. Boermeester, M.A.; van Leeuwen, P.A.; Coyle, S.M.; Wolbink, G.J.; Hack, C.E. and Lowry, S.F. (1995) Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch. Surg., 130, 739-748.
117. Gruber, A.; Harker, L.A.; Hanson, S.R.; Kelly, A.B. and Griffin, J.H. (1991) Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation, 84, 2454- 2462.
118. Gruber, A.; Marzec, U.M.; Bush, L.; Di Cera, E.; Fernandez, J.A.; Berny, M.A.; Tucker, E.I.; McCarty, O.J.; Griffin, J.H. and Hanson, S.R. (2007) Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood, 109, 3733-3740.
119. Aoki, Y.; Ota, M.; Katsuura, Y.; Komoriya, K. and Nakagaki, T. (2000) Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats. Arzneimittel Forschung, 50, 809-815.
120. Bernard, G.R.; Ely, E.W.; Wright, T.J.; Fraiz, J.; Stasek, J.E.Jr.; Russell, J.A.; Mayers, I.; Rosenfeld, B.A.; Morris, P.E.; Yan, S.B. and Helterbrand, J.D. (2001) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit. Care Med., 29, 2051-2059.
121. Dhainaut, J.F.; Yan, S.B.; Joyce, D.E.; Pettila, V.; Basson, B.; Brandt, J.T.; Sundin, D.P. and Levi, M. (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J. Thromb. Haemost., 2, 1924-1933.
122. Abraham, E.; Laterre, P.F.; Garg, R.; Levy, H.; Talwar, D.; Trzaskoma, B.L.; Francois, B.; Guy, J.S.; Bruckmann, M.; Rea- Neto, A.; Rossaint, R.; Perrotin, D.; Sablotzki, A.; Arkins, N.; Utterback, B.G. and Macias, W.L. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med., 353, 1332-1341.
123. Vincent, J.L.; Bernard, G.R.; Beale, R.; Doig, C.; Putensen, C.; Dhainaut, J.F.; Artigas, A.; Fumagalli, R.; Macias, W.; Wright, T.; Wong, K.; Sundin, D.P.; Turlo, M.A. and Janes, J. (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit. Care Med., 33, 2266-2277.
124. Kanji, S.; Perreault, M.M.; Chant, C.; Williamson, D. and Burry, L. (2007) Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med., 33, 517-523.
125. Bertolini, G.; Rossi, C.; Anghileri, A.; Livigni, S.; Addis, A. and Poole, D. (2007) Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med, 33, 426-434.
126. Gando, S.; Sawamura, A.; Hayakawa, M.; Hoshino, H.; Kubota, N. and Oshiro, A. (2006) First day dynamic changes in antithrombin III activity after supplementation have a predictive value in critically ill patients. Am. J. Hematol., 81, 907-914.
127. Fourrier, F.; Chopin, C.; Huart, J.J.; Runge, I.; Caron, C. and Goudemand, J. (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest, 104, 882-888.
128. Blauhut, B.; Kramar, H.; Vinazzer, H. and Bergmann, H. (1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb. Res., 39, 81-89.
129. Vinazzer, H. (1987) Clinical use of antithrombin III concentrates. Vox Sang, 53, 193-198.
130. Kienast, J.; Juers, M.; Wiedermann, C.J.; Hoffmann, J.N.; Ostermann, H.; Strauss, R.; Keinecke, H.O.; Warren, B.L. and Opal, S.M. (2006) Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J. Thromb. Haemost., 4, 90-97.
131. Laterre, P.F.; Opal, S.M.; Abraham, E.; LaRosa, S.P.; Creasey, A.A.; Xie, F.; Poole, L. and Wunderink, R.G. (2009) A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit. Care, 13, R36.
132. Jaimes, F.; De La Rosa, G.; Morales, C.; Fortich, F.; Arango, C.; Aguirre, D. and Munoz, A. (2009) Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit. Care Med., 37, 1185-1196.
133. Griffin, M.P.; Gore, D.C.; Zwischenberger, J.B.; Lobe, T.E.; Hall, M.; Traber, D.L. and Herndon, D.N. (1990) Does heparin improve survival in experimental porcine gram-negative septic shock? Circ. Shock, 31, 343-349.
134. Tanaka, T.; Tsujinaka, T.; Kambayashi, J.; Higashiyama, M.; Yokota, M.; Sakon, M. and Mori, T. (1990) The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model. Thromb. Res., 60, 321-330.
135. Meyer, J.; Cox, C.S.; Herndon, D.N.; Nakazawa, H.; Lentz, C.W.; Traber, L. D. and Traber, D.L. (1993) Heparin in experimental hyperdynamic sepsis. Crit. Care Med., 21, 84-89.
136. Pernerstorfer, T.; Hollenstein, U.; Hansen, J.; Knechtelsdorfer, M.; Stohlawetz, P.; Graninger, W.; Eichler, H.G.; Speiser, W. and Jilma, B. (1999) Heparin blunts endotoxin-induced coagulation activation. Circulation, 100, 2485-2490.